Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07098169 · ClinicalTrials.gov registry record · NA

Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy

A NA study of Schizoaffective Disorder and Schizophrenia Disorders, sponsored by University of California, San Diego.

Recruiting
Registry status
NA
Development phase
201
Enrollment target
3
Study locations

NCT07098169: Recruiting NA study of Schizoaffective Disorder and Schizophrenia Disorders, sponsored by University of California, San Diego.

NCT07098169 is a NA study of Schizoaffective Disorder and Schizophrenia Disorders that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 201 participants, above the 170-participant average among 103 other Schizoaffective Disorder trials with a reported enrollment target (18% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07098169, a NA study of Schizoaffective Disorder and Schizophrenia Disorders, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
NA
Development phase
201 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to evaluate the effectiveness of a psychosocial intervention called iTEST for people with psychotic disorders that targets introspective accuracy, or the ability to accurately gauge ones abilities. iTEST combines daily cognitive training on a mobile device with coaching that addresses recovery goals. In this trial, we will randomize people to one of two interventions conditions, iTEST or a control condition that receives coaching and cognitive training that does not emphasize introspective accuracy. Both interventions will take place over 12 weeks and participants will be asked to complete assessments at baseline, 6 weeks, 12 weeks, and 24 weeks. The primary outcome of the study is community functioning. Participants will be from three metropolitan areas: San Diego, Dallas, or Miami.

Primary Outcome

Measure of participant's community functioning rated by an informant. Scale scores range from 43 to 215 with higher scores reflecting better functioning.

Interventions

  • BEHAVIORAL Active Control
  • BEHAVIORAL iTEST

Study Locations (3)

California

  • UC San Diego - San Diego

Florida

  • University of Miami - Miami

Texas

  • University of Texas at Dallas - Dallas

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2025-09-01
Est. Completion 2028-04-01
Phase NA
University of California, San Diego

775 total trials

What NCT07098169 shows while recruiting

NCT07098169 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 170-participant average among 103 other Schizoaffective Disorder trials with a reported enrollment target (18% higher).

The record links to 3 conditions, with Schizoaffective Disorder appearing as the primary indexed condition, and to 2 interventions - of which Active Control is the first listed.

NCT07098169 reports a single indexed study location in California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07098169 about?

NCT07098169 is a clinical study titled "Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy". The purpose of this study is to evaluate the effectiveness of a psychosocial intervention called iTEST for people with psychotic disorders that targets introspective accuracy, or the ability to accurately gauge ones abilities. iTEST combines daily cognitive training on a mobile device with coaching ...

What is the current status of trial NCT07098169?

This trial is currently recruiting. It is a NA study. The enrollment target is 201 participants. The study started on 2025-09-01. Estimated completion is 2028-04-01.

What conditions does trial NCT07098169 study?

This clinical trial studies the following conditions: Schizoaffective Disorder, Schizophrenia Disorders, Psychotic Disorder.

What interventions are being tested in trial NCT07098169?

The interventions under investigation include: Active Control (BEHAVIORAL), iTEST (BEHAVIORAL).

Who is sponsoring clinical trial NCT07098169?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07098169 being conducted?

This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizoaffective Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07098169's enrollment target sits among peer trials

201 18th of 103 higher than 86 of 103 other Schizoaffective Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizoaffective Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07098169, the US trial registry maintained by the National Library of Medicine. NCT07098169 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.